CD34 Positive Cells Mobilized with Chemotherapy Plus Recombinant Human Growth Hormone (rhGH) and Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) Allows Sustained Engraftment in Previously Non-Mobilizer Patients

Autor:	Mirella Marini, Emilio Ferrari, Alessandro Re, Camillo Almici, Chiara Cattaneo, Giuseppe Rossi, Simona Braga, Piero Ferremi, Rosanna Verardi
Rok vydání:	2005
Předmět:	Oncology Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Immunology CD34 Cell Biology Hematology Biochemistry Granulocyte colony-stimulating factor Regimen Haematopoiesis Tolerability Internal medicine Absolute neutrophil count Medicine Progenitor cell business
Zdroj:	Blood. 106:5259-5259
ISSN:	1528-0020 0006-4971
Popis:	The availability of adequate amounts of peripheral blood progenitor cells (PBPC) is a prerequisite for the feasibility of high-dose therapy program in patients with neoplastic diseases. Due to prior chemio-radiotherapy or disease related factors, 20–30% of patients fails to mobilize sufficient amounts of PBPC. Therefore, non-mobilizer patients cannot complete their therapeutic program. The aims of the present study were: 1) to evaluate the combination rhGH+rhG-CSF after chemiotherapy as a mobilization regimen in previously non-mobilizers patients; 2) to assess safety and tolerability of rhGH+rhG-CSF treatment; 3) to evaluate hematopoietic recovery after reinfusion of rhGH+rhG-CSF mobilized PBPC. After informed consent, three patients (2 male, 1 female), that failed a previous mobilization cycle, were remobilized with chemotherapy plus rhGH (100μg/Kg/d, sc) and rhG-CSG (5μg/Kg/d, sc). Case Disease TNC (x 108/Kg) CD34+ (x 106/Kg) CFC (x 106/Kg) LTC-IC (x 104/Kg) 1 LNH 8.5 7.6 5.68 15.9 2 LNH 18 6.2 3.57 5.0 3 MM 15 1.3 1.26 12.0 No specific side effects were noticed due to rhGH treatment. Reinfusionof PBPC after myeloablative therapy resulted in hematopoietic recovery with 16, 9, 11 days respectively to reach an absolute neutrophil count ≥ 500/μl and 24, 15, 15 days respectively to reach a platelet count ≥ 50000/μl. Hematopoietic engraftment is complete and sustained with a follow-up of 18, 11 and 9 months, respectively. In conclusion our data confirm that the addition of rhGH to rhG-CSF allows mobilization and collection of PBPC in previously non-mobilizer patients, and therefore the programmed high-dose therapy program can be satisfactorily completed, with sustained hematopoietic recovery.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d51faa67d858a2261d608f3e74500b48 https://doi.org/10.1182/blood.v106.11.5259.5259 Zobrazit plný text záznamu